J Chancellor

1.1k total citations
27 papers, 852 citations indexed

About

J Chancellor is a scholar working on Economics and Econometrics, Epidemiology and Infectious Diseases. According to data from OpenAlex, J Chancellor has authored 27 papers receiving a total of 852 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Economics and Econometrics, 5 papers in Epidemiology and 4 papers in Infectious Diseases. Recurrent topics in J Chancellor's work include Influenza Virus Research Studies (4 papers), Respiratory viral infections research (4 papers) and HIV/AIDS Research and Interventions (4 papers). J Chancellor is often cited by papers focused on Influenza Virus Research Studies (4 papers), Respiratory viral infections research (4 papers) and HIV/AIDS Research and Interventions (4 papers). J Chancellor collaborates with scholars based in United Kingdom, United States and France. J Chancellor's co-authors include Michael Drummond, Elke Hunsche, Samuel Aballéa, Sibilia Quilici, Mickael Löthgren, A Garcia-Cebrian, Brigitta U. Monz, Dominique Simon, Trong Kim Le and Gérard Saïd and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and CHEST Journal.

In The Last Decade

J Chancellor

27 papers receiving 813 citations

Peers

J Chancellor

PHARM

EPIDE

PHYSI

GHP

Roman Casciano United States

Denis Getsios United States

Rosa Morros Spain

Kate Traynor United States

Ziyad S. Almalki Saudi Arabia

Ishak A. Mansi United States

Junling Wang United States

Antònia Agustí Spain

Melanie D. Whittington United States

Antonio Gimeno‐Miguel Spain

Roman Casciano United States

J Chancellor

251 ×1.0

75 ×0.4

PHARM

214 ×1.3

EPIDE

30 ×0.2

PHYSI

61 ×0.5

GHP

Citations per year, relative to J Chancellor J Chancellor (= 1×) peers Roman Casciano

Countries citing papers authored by J Chancellor

Since Specialization

Citations

This map shows the geographic impact of J Chancellor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J Chancellor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J Chancellor more than expected).

Fields of papers citing papers by J Chancellor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J Chancellor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J Chancellor. The network helps show where J Chancellor may publish in the future.

Co-authorship network of co-authors of J Chancellor

This figure shows the co-authorship network connecting the top 25 collaborators of J Chancellor. A scholar is included among the top collaborators of J Chancellor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J Chancellor. J Chancellor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chancellor, J, et al.. (2011). Stated Preferences of Physicians and Chronic Pain Sufferers in the Use of Classic Strong Opioids. Value in Health. 15(1). 106–117. 26 indexed citations

Clements, Karen M., et al.. (2011). Cost-Effectiveness of a Recommendation of Universal Mass Vaccination for Seasonal Influenza in the United States. Value in Health. 14(6). 800–811. 23 indexed citations

Chancellor, J, et al.. (2010). Cost-Effectiveness of Maraviroc for Antiretroviral Treatment-Experienced HIV-infected Individuals in Mexico. Value in Health. 13(8). 903–914. 7 indexed citations

Chancellor, J, et al.. (2010). A Microsimulation of the Cost-effectiveness of Maraviroc for Antiretroviral Treatment-Experienced HIV-Infected Individuals. HIV Clinical Trials. 11(2). 80–99. 15 indexed citations

Quilici, Sibilia, J Chancellor, Mickael Löthgren, et al.. (2009). Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurology. 9(1). 6–6. 155 indexed citations

Chancellor, J, et al.. (2008). Preferences of Patients with Diabetes Mellitus for Inhaled versus Injectable Insulin Regimens. PharmacoEconomics. 26(3). 217–234. 34 indexed citations

Aballéa, Samuel, J Chancellor, Peter Wutzler, et al.. (2007). The Cost-Effectiveness of Influenza Vaccination for People Aged 50 to 64 Years: An International Model. Value in Health. 10(2). 98–116. 65 indexed citations

Gasparini, Roberto, Carlo Lucioni, Filippo Ansaldi, et al.. (2007). Studio costo-efficacia della vaccinazione influenzale per gli italiani di età compresa tra 50 e 64 anni. 9(2). 91–101. 5 indexed citations

Aballéa, Samuel, Michelangela Barbieri, Marga Martı́n, et al.. (2007). The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: A model-based analysis for Spain. Vaccine. 25(39-40). 6900–6910. 24 indexed citations

10.

Aballéa, Samuel, J Chancellor, Maria Raikou, et al.. (2007). Cost‐effectiveness analysis of oxaliplatin compared with 5‐fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer. 109(6). 1082–1089. 55 indexed citations

11.

Barbieri, Marco, et al.. (2005). Variability of Cost-Effectiveness Estimates for Pharmaceuticals in Western Europe: Lessons for Inferring Generalizability. Value in Health. 8(1). 10–23. 97 indexed citations

12.

Quilici, Sibilia, J Chancellor, Grant Maclaine, et al.. (2005). Cost-effectiveness of acarbose for the management of impaired glucose tolerance in Sweden. International Journal of Clinical Practice. 59(10). 1143–1152. 13 indexed citations

13.

Aballéa, Samuel, J Chancellor, Maria Raikou, et al.. (2005). CN1 COST-EFFECTIVENESS ANALYSIS OF OXALIPLATIN/5-FU/LV IN ADJUVANT TREATMENT OF STAGE III COLON CANCER IN THE UK AND GERMANY. Value in Health. 8(6). A21–A21. 1 indexed citations

14.

Drummond, Michael, Margaret Hux, J Chancellor, et al.. (2003). An Economic Evaluation of Sequential IV/po Moxifloxacin Therapy Compared to IV/po Co-amoxiclav With or Without Clarithromycin in the Treatment of Community-Acquired Pneumonia*. CHEST Journal. 124(2). 526–535. 45 indexed citations

15.

Barbieri, Marco, et al.. (2003). PHP4 ARE THE RESULTS OF ECONOMIC EVALUATIONS GENERALIZABLE? EVIDENCE FROM STUDIES OF PHARMACEUTICALS IN WESTERN EUROPE. Value in Health. 6(6). 710–711. 1 indexed citations

16.

Chancellor, J, et al.. (2001). Economic Evaluation of Celecoxib, a New Cyclo-Oxygenase 2 Specific Inhibitor, in Switzerland. PharmacoEconomics. 19(Supplement 1). 59–75. 51 indexed citations

17.

Burke, Thomas, et al.. (2001). An Economic Model for Determining the Costs and Consequences of Using Various Treatment Alternatives for the Management of Arthritis in Canada. PharmacoEconomics. 19(Supplement 1). 49–58. 50 indexed citations

18.

Hunsche, Elke, et al.. (2001). The Burden of Arthritis and Nonsteroidal Anti-Inflammatory Treatment. PharmacoEconomics. 19(Supplement 1). 1–15. 38 indexed citations

19.

Trueman, Paul, et al.. (1999). Research into the use of health economics in decision making in the United Kingdom—Phase II. Health Policy. 46(2). 143–157. 72 indexed citations

20.

Chancellor, J, Andrew Hill, Caroline Sabin, Kit N. Simpson, & Mike Youle. (1997). Modelling the Cost Effectiveness of Lamivudine/Zidovudine Combination Therapy in HIV Infection. PharmacoEconomics. 12(1). 54–66. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact